<DOC>
	<DOCNO>NCT00293657</DOCNO>
	<brief_summary>To determine whether single dose intravenous lornoxicam superior intravenous placebo acute treatment moderate severe headache associate single migraine attack patient history migraine . Two-thirds patient study receive single dose intravenous lornoxicam ( 8mg 16 mg ) one-third patient receive single dose intravenous placebo .</brief_summary>
	<brief_title>Study Lornoxicam Placebo Acute Treatment Headache Migraine .</brief_title>
	<detailed_description>The headache migraine primary symptom disorder estimate affect approximately 10 % population develop country , majority person migraine female age 20 50 year . Patients migraine desire rapid complete relief headache decrease frequency recurrence 24 hour treatment . Current treatment migraine often provide incomplete pain relief additional acute treatment need . Lornoxicam member NSAID class anti-inflammatory drug show effective acute management postoperative pain arthritis . The current study evaluate efficacy single dos lornoxicam , administer intravenously , treatment headache migraine determine possible future us drug condition .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Lornoxicam</mesh_term>
	<mesh_term>Piroxicam</mesh_term>
	<criteria>Subjects must demonstrate history migraine headaches accord International Headache Society ( IHS ) criteria 1.1 1.2 ( 2004 ) , first migraine prior age 50 , average migraine headache frequency 26 migraine per month , moderate severe pain intensity , last 6 month prior screen . Subjects willing come study site he/she onset headache migraine receive intravenous dose study medication willing remain investigator 's clinic least 2 hour intravenous dose collection study data ( Subject discharge home 2 hour postdose evaluation complete ) . Subjects pregnant . Subjects know allergic reaction intolerance NSAIDs ; subject aspirin nonsteroidal antiinflammatory/analgesic drug induce symptom asthma , rhinitis nasal polyp . Subject receive medication know suspected drug interaction lornoxicam . These include : warfarin anticoagulant , digoxin , probenecid , methotrexate , lithium , aspirin , cimetidine , cyclosporine and/or furosemide . Subjects nonmigraine ( i.e. , tensiontype , sinus , etc . ) headache frequency &gt; 15 days/month 3 month ( 90 day ) prior screen . Subjects experience great average 6 migraine attack per month and/or &gt; 15 migraine day per month 6 month prior screen . Subjects history document gastrointestinal ulceration past six month hospitalization gastrointestinal bleeding past year . Subjects history impair renal function and/or history kidney disease , interstitial nephritis , nephrotic syndrome , and/or peripheral edema . Subjects history heart disease certain related condition . Subjects uncontrolled hypertension hypertension difficult control medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>